Drug Shortage Report for MABCAMPATH

Last updated on 2020-06-18 History
Report ID 106962
Drug Identification Number 02290960
Brand name MABCAMPATH
Common or Proper name Alemtuzumab
Company Name SANOFI GENZYME, A DIVISION OF SANOFI-AVENTIS CANADA INC
Market Status MARKETED
Active Ingredient(s) ALEMTUZUMAB
Strength(s) 30MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS
Packaging size 1 ml vial
ATC code L04AA
ATC description IMMUNOSUPPRESSANTS
Reason for shortage Other (Please describe in comments)
Anticipated start date 2020-06-01
Actual start date 2020-05-15
Estimated end date 2020-09-30
Actual end date 2020-06-15
Shortage status Resolved
Updated date 2020-06-18
Company comments Shortage due to Production Delay. An allocation strategy will be implemented restricting use of MabCampath to patients whose treating physicians show, they have a special need in the absence of other alternatives. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments
Tier 3 Status No
Company contact information Customer service contact info: 1-800-265-7927

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v12 2020-06-18 French Compare
v11 2020-06-18 English Compare
v10 2020-05-16 English Compare
v9 2020-05-15 French Compare
v8 2020-05-15 English Compare
v7 2020-05-15 English Compare
v6 2020-03-11 French Compare
v5 2020-03-11 English Compare
v4 2020-03-11 English Compare
v3 2020-02-21 French Compare
v2 2020-02-21 French Compare
v1 2020-02-21 English Compare

Showing 1 to 12 of 12